Navigation Links
Amylin Pharmaceuticals Reports Third Quarter Financial Results
Date:10/19/2011

financial results. A slide presentation accompanying the conference call is available through the "Investors" section of Amylin's corporate website at www.amylin.com.

To access the webcast, please log on to www.amylin.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (800) 857-5738 (U.S./Canada) or (415) 228-4970 (international), participant passcode number 7156306. A replay of the call will also be available by phone beginning approximately two hours after the close of the call and can be accessed at (866) 415-3327 (U.S./Canada) or (203) 369-0696 (international).

Note Regarding Use of Non-GAAP Financial Measures Amylin reports non-GAAP operating income or loss excluding non-cash items and other items such as restructuring charges, which is a non-GAAP financial measure. The Company believes that investors' understanding of its progress towards its stated goal of generating sustainable positive non-GAAP operating results is enhanced by this disclosure. In addition, the Company refers to this non-GAAP financial information with its analysis of the Company's financial performance. This non-GAAP financial measure should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.  

About Amylin PharmaceuticalsAmylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amylin Pharmaceuticals to Webcast Third Quarter Results
2. Amylin Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
3. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
4. Amylin Pharmaceuticals to Webcast Second Quarter Results
5. U.S. District Court Rules in Favor of Lilly in Amylin Litigation
6. Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order
7. Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly
8. Lilly Comments on Court Ruling in Amylin Litigation
9. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
10. Lilly Provides Its Perspective in Response to Amylin Lawsuit
11. Lilly Provides Statement in Response to Amylin Lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... Preclinical findings of amylin/leptin synergy and translational Phase 2A, ... of the National ... States of America, SAN DIEGO, May 5 ... initiation of a Phase 2B clinical study,evaluating various dosing ...
... BETHESDA, Md., May 5 Vaccines don,t just keep ... who can earn,higher wages and save more money, according ... Harvard School of Public Health., Bloom, who has ... be the keynote speaker at the 11th Annual Conference ...
Cached Medicine Technology:Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity 2Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity 3Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity 4Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity 5Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains 2Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains 3Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains 4Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains 5Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains 6
(Date:7/10/2014)... Estonian-born Katerina Alba,s research at the University of Huddersfield ... the most popular emulsion-based food products such as ... is starting to gain an international profile for her ... and food science at the University and now she ... with her supervisor, Dr Vassilis Kontogiorgos, she is investigating ...
(Date:7/10/2014)... A neuroscientist at Rutgers University-Newark says the human brain ... a finding that could provide a better understanding ... conditions that afflict an estimated 13.6 million Americans. , ... , Michael Cole, an assistant professor at the Center ... brain architecture of a person at rest is basically ...
(Date:7/10/2014)... sarcomas research group at the Bellvitge Biomedical Research Institute ... been tested in 19 patients a new therapeutic combination ... indicate that the new treatment could stabilize the growth ... the British Journal of Cancer ., Sarcomas ... complex since there are several subtypes. It can affect ...
(Date:7/10/2014)... 10, 2014) Men who experience hot flashes are ... find relief from their silent suffering if they ... findings from a Baylor University case study., After seven ... had uncontrolled hot flashes following prostate cancer surgery showed ... also an impressive improvement in sleep quality, according to ...
(Date:7/9/2014)... that sudden, acute episodes of low back pain are ... air pressure, wind direction and precipitation. Findings published in ... the American College of Rheumatology (ACR), indicate that the ... wind speed or wind gusts, but was not clinically ... (WHO) nearly everyone experiences low back pain at some ...
Breaking Medicine News(10 mins):Health News:World interest in research work on the benefits of the Okra plant 2Health News:Working to loosen the grip of severe mental illness 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Low back pain? Don't blame the weather 2
... might spur obesity, German study finds , FRIDAY, Aug. 7 ... financial debt, German researchers suggest. , In their study, Eva ... the weight of more than 9,000 people. , They found ... debt were classified as obese, a full quarter of those ...
... , , CENTENNIAL, Colo., Aug. 7 ... and soft tissue allografts for use in surgical procedures, announced today that ... in the Healthcare category of the Top Company awards program hosted by ... is hosting the business awards program for the 22nd consecutive year. ...
... , , , ... WCRX ) today announced its results for the quarter ... 2009 increased 7.1% to $250.8 million over the prior year quarter. ... sales of DORYX, LOESTRIN 24 FE and ESTRACE Cream which were ...
... ... onsite employee health services and technology solutions, today announced the opening of a Chicago field ... region. , ... August 7, 2009 -- Marathon Health, a leading provider of onsite employee health services ...
... and most expensive patients need fewer health care resources and ... nurse-physician primary care team that tracks their health and offers ... Johns Hopkins Bloomberg School of Public Health. The research, published ... that in the first eight months of a randomized controlled ...
... rate of heart attack, tripled rate of death seen ... New research shows that men diagnosed with the chest ... neither artery-opening angioplasty nor coronary-bypass surgery reduced long-term mortality ... newly diagnosed with angina at 40 primary-care practices in ...
Cached Medicine News:Health News:Slide Into Debt Could Bring Wider Waistline 2Health News:AlloSource Chosen as Healthcare Finalist in 2009 'Top Companies' 2Health News:AlloSource Chosen as Healthcare Finalist in 2009 'Top Companies' 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance 18Health News:Marathon Health Expands Midwest Presence 2Health News:Guided care reduces cost of health care for older persons with chronic conditions 2Health News:Men With Angina Do Worse Than Women 2Health News:Men With Angina Do Worse Than Women 3
1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride. 1.5% agararose...
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
... flowing powder. pH: pH(4.7%, H 2 O): ... Yeast Extract: 47% Potassium Phosphate Dibasic: 25% Potassium ... 47 gm powder per liter of purified water. ... and recombinant proteins than LB media by allowing ...
1.2% Tryptone, 2.4% Yeast Extract, 0.4% Glycerol, with 100ml of 10x Phosphate buffer supplement (0190-01)....
Medicine Products: